Abbott Laboratories slightly lifted its annual profit forecast on Wednesday after beating Wall Street estimates for quarterly earnings. The company attributed its strong performance to robust sales of its medical devices, including continuous glucose monitors and other products. Abbott also narrowed its full-year financial guidance amid the strength in medical device sales. The company expects a strong outlook for 2025 with high single-digit top-line growth and 10% EPS growth, supported by a robust pipeline and strategic market positions.